Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso